USA's PhRMA new line up sees Pfizer's Kindler become chairman, with European drug chief elected to follow

19 March 2010

The annual meeting of the Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday saw the election of US drug behemoth Pfizer's chairman and chief executive, Jeffrey Kindler, elected as board chairman of at the trade association. Also elected were French major Sanofi-Aventis CEO Christopher Viehbacher as chairman-elect, and John Lechleiter, chairman, president and CEO of Eli Lilly, as board treasurer. Mr Kindler succeeds David Brennan, CEO of Anglo-Swedish drug major AstraZeneca.

Applauding Mr Brennan's tenure, as 'a tireless advocate for patient-centered policies here in the USA and abroad,' PhRMA president and CEO Billy Tauzin said that, during this time, the PhRMA 'broadened its scope by welcoming several smaller biopharmaceutical companies as members, we continued to highlight the critical work being done to develop new innovative treatments for orphan and rare diseases, and we reaffirmed our commitment to strengthening the US health care system by supporting comprehensive health care reform."

What the in-comers have to say

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >